Groundbreaking Ebola Vaccine Trial Initiated by Oxford and Serum Institute

The University of Oxford and the Serum Institute of India have launched the first human clinical trial for a vaccine targeting the Bundibugyo strain of the Ebola virus. This groundbreaking trial aims to assess the safety and immune response of the ChAdOx1 BDBV vaccine, developed specifically for this strain, which currently lacks an approved vaccine. With 50 healthy volunteers participating, the trial represents a crucial step in combating Ebola outbreaks, particularly in vulnerable regions. If successful, this vaccine could become the first approved solution against the Bundibugyo strain, enhancing global health efforts to prevent future outbreaks.

By Narendra Chaudhary Jul 14, 2026, 17:01 IST

Introduction to the Vaccine Trial

In a significant advancement for global health, researchers from the University of Oxford, in collaboration with the Serum Institute of India (SII), have commenced the first human clinical trial of a vaccine aimed at combating the Bundibugyo strain of the Ebola virus. This experimental vaccine, named ChAdOx1 BDBV, is the first of its kind specifically developed for this strain, which currently lacks an approved vaccine. The Phase I trial is a crucial step in addressing emerging Ebola outbreaks, particularly in African regions where the Bundibugyo virus poses a growing threat. The primary focus of this trial is to evaluate the vaccine's safety and its ability to elicit a protective immune response before progressing to larger clinical trials.

The Need for a Bundibugyo Ebola Vaccine

Why is a Bundibugyo Ebola vaccine needed?

The Ebola virus disease is a severe and often lethal condition caused by various species of the Ebola virus. While there are licensed vaccines for the Zaire strain, no approved vaccine exists for the Bundibugyo strain, leaving populations at risk during outbreaks. The virus is transmitted through direct contact with the bodily fluids of an infected individual or contaminated surfaces. Without immediate medical intervention, Ebola can result in multiple organ failure and death. Symptoms typically manifest between 2 to 21 days post-exposure and may include:

High fever
Severe weakness
Headache
Muscle pain
Vomiting
Diarrhea
Abdominal pain
Severe cases may involve unexplained bleeding or bruising

Details About the New Vaccine

About the new vaccine

The ChAdOx1 BDBV vaccine has been developed by the Oxford Vaccine Group and the Pandemic Sciences Institute. It utilizes the same chimpanzee adenoviral vector (ChAdOx1) platform that was instrumental in creating the Oxford-AstraZeneca COVID-19 vaccine, which provided protection to millions globally during the pandemic. Researchers are optimistic that this established platform will expedite the development process while ensuring robust immune protection against the Bundibugyo virus.

Human Trial Participation

What will the human trial involve?

The Phase I clinical trial will take place in Oxford, enrolling 50 healthy volunteers aged between 18 and 55 years. Participants will undergo thorough medical evaluations before receiving the investigational vaccine. Over the subsequent weeks and months, researchers will meticulously monitor the participants for vaccine safety, potential side effects, immune responses, and antibody production. Should the vaccine demonstrate a favorable safety profile and induce a strong immune response, it will progress to larger Phase II and Phase III trials to assess its effectiveness in preventing Ebola infection.

Role of the Serum Institute

Serum Institute's role

The Serum Institute of India, recognized as the largest vaccine manufacturer globally by volume, is responsible for producing the vaccine for clinical evaluation. The company has already provided approximately 4,000 investigational doses for this trial and is preparing for larger-scale production if the vaccine proves effective. Its extensive experience in producing billions of vaccine doses, including during the COVID-19 pandemic, positions it to facilitate rapid and affordable access for nations facing future Ebola outbreaks.

Importance of the Trial

Why does this trial matter?

Scientists at Oxford highlighted that the vaccine candidate reached human testing a mere 57 days after the World Health Organization declared the Bundibugyo Ebola outbreak a Public Health Emergency of International Concern. This underscores the potential of international collaboration to expedite vaccine development during health crises. The Chief Investigator of the study described this first-in-human trial as a significant milestone following years of scientific research, manufacturing, and regulatory preparation. Adar Poonawalla, CEO of SII, emphasized the importance of speed, preparedness, and global collaboration in effectively responding to future outbreaks and ensuring vaccine accessibility for at-risk countries. He stated, "We are pleased to support this important Phase I trial by supplying investigational doses of the ChAdOx1 BDBV vaccine candidate for clinical evaluation. During outbreaks, speed, preparedness, and global collaboration are essential to advancing vaccine candidates quickly and responsibly.” Although the ChAdOx1 BDBV vaccine is still in the early stages of clinical testing, the initiation of this first human trial marks a significant step forward in Ebola preparedness. If subsequent studies validate its safety and efficacy, it could become the first approved vaccine against the Bundibugyo strain of Ebola, thereby enhancing global efforts to prevent deadly outbreaks and safeguard vulnerable communities.